Diphtheria is a fulminant bacterial disease caused by toxigenic strains of Corynebacterium diphtheriae whose local and systemic manifestations are due to the action of the diphtheria toxin (DT). The vaccine which is used to prevent diphtheria worldwide is a toxoid obtained by detoxifying DT. Although associated with high efficacy in the prevention of disease, the current anti-diphtheria vaccine, one of the components of DTP (diphtheria, tetanus and pertussis triple vaccine), may present post vaccination effects such as toxicity and reactogenicity resulting from the presence of contaminants in the vaccine that originated during the process of production and/or detoxification. Therefore, strategies to develop a less toxic and at the same time economically viable vaccine alternatives are needed to improve existing vaccines in use worldwide. In this study, the Moreau substrain of BCG which is used in Brazil as a live vaccine against human tuberculosis was genetically modified to carry and express the gene encoding for the diphtheria toxin fragment B (DTB). As such, the DNA sequence encoding the dtb gene was cloned into the pUS977 shuttle vector for cytoplasmic expression and successfully introduced into BCG cells by electroporation. Mice immunized with recombinant BCG expressing DTB showed seroconversion with the detection of specific antibodies against DTB. Also, rBCGs stably expressing DTB persisted up to 60 days in the absence of selective pressure in mice and cell viability did not change significantly during the period tested. Finally, immune sera from BALB/c mice vaccinated with rBCGpUS977dtb PW8 were preliminarily tested for their capacity of neutralizing the diphtheria toxin in the Vero Cells assay.
Introduction
Corynebacterium diphtheriae, one of 59 described species in the Corynebacterium genus, causes the highly contagious infection diphtheria in humans [1] [2] [3] . C. diphtheriae produces diphtheria toxin (DT) and a pseudomembrane adherent to the tonsils, pharynx, and/or nose. The local and systemic manifestations of diphtheria are mainly related to the action of DT, which is the most studied virulence factor of this species [4] [5] [6] [7] . DT is a polypeptide of 535 amino acids with a molecular weight of approximately 58.3 kDa, which is proteolytically cleaved after secretion into two fragments with distinct activities. The aminoterminal fragment A (DTA) is responsible for toxicity and the nontoxic carboxyl fragment (DTB) with 341 amino acids is responsible for adherence and internalization of the DT [8] [9] .
Mycobacterium bovis Bacillus Calmette-Guerin (BCG) is used as a vaccine for the control of tuberculosis, is currently the most widely used vaccine in the world and has been given to more than three billion people since 1921 [10] [11] .
For this reason, BCG is among the best live vector candidates for delivery of protective antigens in vivo, especially in developing countries where the cost of vaccines is a major issue. BCG is able to elicit potent Th1-mediated immune responses and requires no additional adjuvant components in its formulation to evoke protective immunity, as demonstrated in several animal models of infectious diseases [12] [13] [14] . Additionally, several other advantages have been associated with the potential use of BCG as an antigen-presenting system such as the ability to induce a long lasting type 1 helper T cell (Th1) immune response and CD8+T-cell triggering with just one dose. BCG can also be given at birth, is one of the most thermostable vaccines to date and can induce mucosal immunity by oral or nasal administration [15] [21] . The major purpose of our study is the development of a safer, less reactogenic and cheaper diphtheria vaccine prototype based on the use of BCG, the vaccine against tuberculosis, as a live delivery vector. In this report we present data on the construction of a new rBCG strain prototype vaccine against diphtheria based on the Brazilian Moreau vaccine substrain of M. bovis BCG, expressing the C. diphtheriae gene dtb PW8 by means of the non-integrative plasmid vector pUS977. Analysis of dtb expression by BCG, structural stability of the pUS977dtb PW8 after vaccination, ability to induce a specific humoral response against the diphtheria toxoid and a prelimi-D. V. Nascimento et al. American Journal of Molecular Biology nary evaluation of the neutralization power of sera from mice immunized with the rBCGpUS977dtb PW8 prototype was carried out. When necessary, kanamycin was added to the mycobacteria media at a concentration of 25 µg/mL for selection of recombinant bacteria.
Materials and

Construction of the pUS977 Expression Vector pUS977dtbpw8
A DNA fragment representing the entire dtb gene subunit was amplified from C. diphtheriae genomic DNA using the primers dtb forward A2633B07 5' CGT CTA GAA GGT AGC TCA TTG TC 3' and dtb A2633B08 reverse 5' GCT CTA GAC CCC ACT ACC TTT C 3', each containing a Xbal restriction site. The resulting 0.965 kb fragment was digested with Xbal and cloned in frame in pUS977, previously cut with the same enzyme, to create the construct pUS977dtb PW8. This construct was amplified in E. coli DH5α and used to transform BCG by electroporation using standard methods [22] . Transformants were later selected by their resistance to kanamycin.
Western Blotting and Localization of Heterologous Proteins in rBCG
After transformation, recombinant BCG strains were selected on 7H10 Middlebrook medium containing kanamycin 25 µg/mL. Several colonies were tested for their plasmid content by the electroduction method described by [23] 
Stability and Persistence of rBCG pUS977dtbPW8 in Human Monocytes (THP-1)
Cultures 
Immunization Procedures
Immunization experiments with 4 -6 week-old male BALB/c mice were con- Briefly, to evaluate the immune response against the rBCG strain, groups of 5 mice (BCG, BCGpUS977, rBCG pUS977dtb PW8 and DTP), were immunized intraperitoneally (i.p.) with 10 6 CFU/0.1 mL in phosphate buffered saline (PBS) containing 0.05% Tween 80 (vol/vol) (Sigma, St Louis, MO) (PBS-T) at day 0 and boosted 9 weeks later. As a control, each animal in a group of 5 received 50 µL of the conventional DPT vaccine. All animals were bled at different time points after priming at the retro-orbital plexus and sera obtained from blood at each point were pooled and later analyzed by enzyme-linked immunosorbent assays (ELISA), which was performed for detection and quantitation of anti-rDTB PW8 mouse antibodies. Sera were collected 4 weeks after immunization, pooled, and tested by ELISA for the presence of antibodies against DTB.
Evaluation of the Structural Stability of the pUS977dtbPW8 Construct from rBCGs Recuperated from Mice
After immunization, recombinant BCGs were recovered out of the spleens of vaccinated mice for evaluation of the structural stability of the pUS977dtb PW8
construct. Thus, constructs were then directly transferred from spleen reisolated rBCGs to E. coli DH5α by electroduction [23] and subsequently recuperated, purified and digested with restriction endonucleases (XbaI or KpnI). The presence (or absence) of structural changes in the construct was evaluated by comparing it with the banding pattern generated by the plasmid preparation used to produce the original transformant, through electrophoresis in 1% agarose gel.
Analysis of the Humoral Immune Response Induced by rBCG pUS977dtbPW8
Serum antibody responses were quantified by ELISA. Briefly, Maxisorp 96-well plates (Nunc International, Rochester, NY) were coated with the diphtheria toxoid (100 µL; 0.05 µg/mL in 0.2 M carbonate buffer/0.2 M bicarbonate pH 9.6; 4˚C overnight), then washed five times with PBS-T, blocked with 4% nonfat dry milk in PBS, and finally incubated with serial dilutions of mouse sera in PBS. After 1 hour at 37˚C, the plates were washed as described above and incubated with HRP-conjugated goat anti-mouse IgG (1:4,000) (Southern Biotechnology Associates, Inc.) in PBS at 37˚C for 1 hour. After another round of washings, antibodies were visualized by adding TMB substrate (100 µL; 10 mg/mL 3, 3', 5, 5' tetramethylbenzidine in citrate phosphate buffer, containing 0.01% hydrogen peroxide. After adding the substrate, the plates were sealed and incubated in the dark at room temperature for 10 min, after which the reaction was stopped by adding 50 µL of a 20% sulphuric acid solution, and the optical density (OD) of the yellow-orange color developed was measured at 450 -492 nm in a spectrophotometer (Biorad). Absorbance values were plotted against serum dilutions.
Vero Cell Method Potency Test
The in vitro Vero cell (CCL-81) method chosen for the purposes of this study is 
Results
The pUS977dtb PW8 expression vector was created on top of the mycobacterial pUS977 plasmid developed by Medeiros et al. (30) through the ligation of the 1051 bp diphtheria toxin dtb DNA amplified by PCR as described above, to the pUS977 XbaI restriction site. The Figure 1 The structural stability of the recombinant plasmid introduced into the BCG should reflect the functional stability of the prototype vaccine with the expression of the target protein for several generations. Also very important is the evidence that the same rBCGs recovered from the spleen of BALB/c mice 60 days after vaccination, when subjected to six consecutive sub-cultures, showed no difference in the ability to express the DTB, thus demonstrating the persistence of functional stability of the rBCG transformed with pUS977dtb PW8 construct.
The size of the protein expressed by the rescued constructs was exactly as expected, and it was also recognized by anti-diphtheria toxoid polyclonal antibodies in western blottings. The infectivity/persistence study carried out in THP-1 human monocytes was done in two independent experiments (8 and 12 days, respectively), in the presence or absence of kanamycin [24] . The rBCGpUS977 dtb pw8 retained full infectivity when compared to non-modified BCG and was able to persist in THP-1 cells up to the maximum time limit tested (12 days) with no plasmid loss in the absence of kanamycin (Figure 2) . Additionally, viability counts of both rBCGpUS977dtb pw8 and non-modified BCG originated from infected THP-1 cells were similar at all time points in both experiments, regardless of the presence of kanamycin, which denotes the stability of the rBCGpUS977dtb pw8 inside a human cell as well, even in the absence of selective pressure. Similarly, the genetic integrity of the pUS977dtb pw8 construct was confirmed later by PCR analyses of plasmids electroeluted to E.coli from rBCGs recovered from THP-1 cells.
In humans, BCG and DPT vaccines are administered by different routes, intradermally for BCG and intramuscularly for DPT. In this study, we chose to use the intraperitoneal route for both rBCG and DPT so that we could compare the response induced by the rBCG vaccine prototype and DPT in the same immunization context. We thus verified that BALB/c mice vaccinated with the rBCGpUS977dtb pw8 were able to mount a specific immune response against the diphtheria toxoid. Sera collected from immunized mice and controls after up to 20 weeks revealed that the anti-DT immune response peaked 4 weeks after the 
Discussion and Conclusions
Since the first transformation of mycobacteria with foreign DNA, the recombinant BCG technology has been used to evaluate the expression of foreign protec- [36] . Although the expression of DT antigens in different bacterial species has been previously done [8] [37]- [41] , in BCG the expressed DT antigens came from the mutant CRM 197 [27] and the diphtheria toxin dtb gene of the PW8 vaccine strain [42] . It is well known that DTB is crucial for the adherence of diphtheria toxin to target cell receptors, a fundamental step in the internalization of the DT toxic fragment A. Thus, if we are able to induce the production of antibodies against DTB with an rBCG engineered to do it so, it is expected that the antibodies generated will interfere with adherence and the internalization process of DT and, consequently, will prevent the toxigenic effects of toxin produced by C. diphtheriae strains.
Despite the advances reached so far, a major limitation of the rBCG technology is the stability of the modified BCG [42] . In the present study, the promoter P AN of M. paratuberculosis [43] subunit of pertussis toxin [30] . Our results showed that, contrary to DTP, the response to the rBCGpUS977dtbpw8 was strong, especially in the 12 -20 week interval. Previous results with rBCG showed that the expression of CRM 197 was found to generate a neutralizing response [27] . In our study the rBCGpUS977d tbpw8 was also able to generate neutralizing antibodies, albeit at low sera dilutions. However, it is important to keep in mind that sera-neutralizing capabilities in mice, guinea pigs, rabbits and humans are not comparable and further studies will have to be done to assure the neutralizing quality of the response generated by the rBCGpUS977dtbpw8. Taken together, the results achieved so far reveal that the new strain rBCGpUS977dtbpw8 developed in our laboratory proved to be genetically stable up to 20 weeks after vaccination and was able to generate a specific humoral response against the target antigen DTB associated to the neutralization of the toxin produced by C. diphtheria. The rBCGpUS977dt bpw8 has a potential application as a vaccine prototype and may as well be useful in future studies of neutralizing immune responses and protection against C. diphtheriae.
